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Aims This study sought to evaluate the feasibility and early outcomes of a percutaneous edge-to-edge repair approach for
mitral valve regurgitation with the MitraClip
w system (Evalve, Inc., Menlo Park, CA, USA).
Methods
and results
Patients were selected for the procedure based on the consensus of a multidisciplinary team. The primary efﬁcacy
endpoint was acute device success deﬁned as clip placement with reduction of mitral regurgitation to  2þ. The
primary acute safety endpoint was 30-day freedom from major adverse events, deﬁned as the composite of death,
myocardial infarction, non-elective cardiac surgery for adverse events, renal failure, transfusion of .2 units of
blood, ventilation for .48 h, deep wound infection, septicaemia, and new onset of atrial ﬁbrillation. Thirty-one
patients (median age 71, male 81%) were treated between August 2008 and July 2009. Eighteen patients (58%) pre-
sented with functional disease and 13 patients (42%) presented with organic degenerative disease. A clip was success-
fully implanted in 19 patients (61%) and two clips in 12 patients (39%). The median device implantation time was
80 min. At 30 days, there was an intra-procedural cardiac tamponade and a non-cardiac death, resulting in a
primary safety endpoint of 93.6% [95% conﬁdence interval (CI) 77.2–98.9]. Acute device success was observed in
96.8% of patients (95% CI 81.5–99.8). Compared with baseline, left ventricular diameters, diastolic left ventricular
volume, diastolic annular septal–lateral dimension, and mitral valve area signiﬁcantly diminished at 30 days.
Conclusion Our initial results with the MitraClip device in a very small number of patients indicate that percutaneous edge-to-
edge mitral valve repair is feasible and may be accomplished with favourable short-term safety and efﬁcacy results.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Moderate or severe mitral regurgitation (MR) is the second most
common valve disease requiring surgical treatment in Europe.
1
Although some controversies about the optimal timing of interven-
tion in asymptomatic patients are currently present, a consensus
existsthatvalvularsurgeryshouldbeadvisedinsymptomaticpatients
with severe MR, as shown by the corresponding class I recommen-
dation in both the American and European clinical guidelines.
2,3
Valve repair, when feasible, is the preferred surgical treatment in
patients with severe MR because of lower perioperative mortality,
improved survival, better preservation of post-operative left
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valve replacement.
2–4 Edge-to-edge repair has been used as a surgical
technique for the treatment of MR since the early 1990s.
5–7 With this
technique, the edge of the middle scallop of the posterior leaﬂet is
sutured to the corresponding portion of the anterior leaﬂet, creating
a point of permanent coaptation of the two leaﬂets and resulting in a
double-oriﬁce.
The MitraClip
w System (Evalve, Inc., Menlo Park, CA, USA) is a
percutaneous edge-to-edge attachment system that mimics the
surgical procedure. This technique creates a tissue bridge
between the anterior and posterior leaﬂets by means of one clip
deployed through transseptal catheterization. Early trials suggested
that percutaneous valve repair with the MitraClip system is feasible
and safe, with 60% of patients being discharged with a clip and
mild or little MR.
8 This report details the preliminary results of
the Italian experience with the MitraClip system.
Methods
Study design
This prospective registry includes 31 patients treated in the two
centres presently performing percutaneous mitral valve repair with the
MitraClip system in Italy, namely Ferrarotto Hospital (FH) of Catania
and San Raffaele Hospital (SRH) of Milan. The study was approved by
the local medical ethic committees. After receiving a complete oral and
written explanation of the issues surrounding the procedure, all patients
signed written consent for inclusion in the study.
MitraClip system and procedural technique
The MitraClip system includes a MitraClip device, a 24-F Steerable
Guide Catheter (SGC), and a Clip Delivery System (CDS). The Clip
is pre-assembled to the tip of the disposable delivery catheter.
Opening, closing, locking, and detaching the clip are all controlled by
the delivery catheter handle mechanism, which is ﬁrmly lodged on a
metal, sterilized external support placed outside the patient, on the
bottom of a small table above the upper leg.
The procedure is performed under general anaesthesia to avoid any
discomfort due to transoesophageal echocardiography (TOE) moni-
toring. Invasive arterial pressure is monitored through the radial or
femoral artery, and a central venous catheter is placed in the right
internal jugular or subclavian vein. The right femoral vein is cannulated
with a 7-F introducer sheath, and a baseline right heart catheterization
is performed. Then the 7-F introducer is exchanged with an 8-F Mullins
sheath (S. Jude Medical, Minnesota, USA) over a 0.32 guidewire, and a
transseptal puncture is performed using a Brockenbrough needle
under TOE guidance. This is a critical point of the procedure,
because the puncture has to be located in the postero-superior part
of the interatrial septum in order to obtain enough room in the left
atrium for a safe and optimal orientation of the steerable distal part
of the CDS (Figure 1). Once the left atrium is entered with the 8-F
sheath, the left pulmonary vein is cannulated using a 6-F multipurpose
catheter (MPA2, Cordis, Johnson & Johnson, Miami, FL, USA) and a
260 cm Amplatz Super stiff guidewire is left in place. After adminis-
tration of 100 IU/kg of unfractioned heparin, the 24-F SGC is intro-
duced in the left atrium and the dilator is carefully and slowly
retrieved for avoiding vacuum air bubbles. The CDS is then advanced
in the left atrium, and the distal steerable part is manipulated in the
atrium for obtaining a perpendicular and central position with
respect to the mitral valve leaﬂets coaptation line. The correct
trajectory of the clip and the perpendicularity of the two arms with
respect to the mitral leaﬂet coaptation line are checked using three
echocardiographic views: (i) the three-chamber in which the left
atrium, left ventricle, and aortic root are visualized; (ii) the dual-
chamber, in which both left atrium and ventricle are obtained, and
(iii) the trans-gastric short axis view to visualize the coaptation line
of the mitral leaﬂets.
Once the system has been aligned, the clip with opened arms is
advanced into the left ventricle and under TOE guidance the arms
grasp the leaﬂets. When a double-oriﬁce has been created and the
echocardiography conﬁrms the regurgitation reduction and the
optimal and stable grasp of both leaﬂets, there are two options: if
the position is suboptimal, the clip can be reopened and repositioned;
if the result is good and the grasp is stable, the clip arms are closed,
locked, and detached and the SGC and CDS are withdrawn
(Figure 2). When necessary, for example, in case of degenerative MR
or ruptured chordae tendineae with wide prolapse, a second clip
can be implanted (Figure 3). Although the implantation of a second
clip is predictable, when a ﬂail is present, the need for a second clip
in other scenarios is evaluated on a case-by-case basis. Right cardiac
catheterization is ﬁnally performed to record the post-procedural
pressure and the ﬁnal results (Figure 4). The guiding catheter is
removed, and venous femoral access is closed using a ‘ﬁgure-of-eight’
superﬁcial stitch.
9
Post-procedural pharmacologic management included aspirin
100 mg lifelong and clopidogrel 75 mg for 3 months in patients
without atrial ﬁbrillation. Patients with atrial ﬁbrillation were pre-
scribed aspirin 100 mg and vitamin K antagonists.
Patient selection
Key inclusion and exclusion criteria are listed in Table 1. Patients were
selected for the procedure if they met basic criteria for intervention
from the European Society of Cardiology Task Force recommendation
on the management of valvular heart disease.
2 Hence, candidates
included patients with moderate to severe (3þ) or severe (4þ) func-
tional or degenerative MR with symptoms or without symptoms but
left ventricular ejection fraction (LVEF) ,60% or left ventricle end sys-
tolic diameter .45 mm. In addition to meeting guidelines criteria,
patients were high-risk candidates for mitral valve surgery including
cardiopulmonary bypass. High risk was established based on the con-
sensus between a local independent cardiologist and a cardiac surgeon
Figure 1 Bicaval and modiﬁed short-axis transoesophageal
echocardiographic views. Transseptal puncture performed by
means of the Brockenbrough needle.
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ity and mortality. Criteria of high risk included European System for
Cardiac Operative Risk Evaluation (EuroSCORE) .20%, hepatic cir-
rhosis, autoimmune disease, severe renal failure requiring
haemodialysis or any contraindication to extracorporeal circulation.
Given that certain leaﬂet anatomy is deemed to hamper a proper
clip positioning on the leaﬂets with sufﬁcient reduction in MR, echocar-
diographic criteria played a crucial role among clinical considerations
for patient selection. These anatomic considerations included: (i) ﬂail
segment width  15 mm or a ﬂail gap  10 mm; (ii) severe bileaﬂet
ﬂail or severe bileaﬂet prolapse; (iii) evidence of calciﬁcation or cleft
of the grasping area; and (iv) lack of both primary and secondary
chordae support (Table 1). As part of pre-interventional screening,
patients underwent trans-thoracic echocardiography, TOE, chest
X-ray, periodontal radiography, and invasive cardiac evaluation with
coronary angiogram, left ventriculography, and right catheterization.
Study endpoints
The primary acute safety endpoint was freedom from major adverse
events (MAEs) at 30 days, deﬁned as the composite of death, myocar-
dial infarction, non-elective cardiac surgery for adverse events, renal
failure, transfusion of .2 units of blood, ventilation for .48 h, deep
wound infection, septicaemia, and new onset of atrial ﬁbrillation.
Echocardiograms were performed according to a pre-speciﬁed pro-
tocol at baseline, pre-discharge, and at 30 days. The primary efﬁcacy
endpoint was acute device success deﬁned as clip implant with
reduction of MR to  2þ, based on current guidelines.
3 MR grade
was assigned as recommended by the American Society of Echocardio-
graphy based on a validated integrative method
10,11 and the consensus
of two expert observers. In case of disagreement, the opinion of a
third observer was obtained and the ﬁnal decision was made by con-
sensus. As vena contracta width and regurgitant oriﬁce area have not
been validated for a double-oriﬁce valve, these parameters were not
included among methods to appraise the severity of MR.
Statistical analysis
Continuous variables were analysed for a normal distribution with the
Shapiro–Wilk test. Continuous variables following a normal distri-
bution are presented as mean+standard deviations and were com-
pared using Student’s unpaired t-test. Variables not following a
normal distribution are expressed as median [interquartile range
(IQR)] and were compared with Mann–Whitney rank sum test.
One-way analysis of variance or Jonckheere–Terpstra test were
used as appropriate for comparisons across multiple groups and to
generate P-values for trend tests. Categorical variables are presented
Figure 3 (A) Two-chamber transesophageal echocardiographic view. Colour-Doppler examination shows severe mitral regurgitation from
the left ventricle (LV) to the left atrium (LA). The two-dimensional image shows a free-ﬂoating chord and the major degree of prolapse of
the posterior leaﬂet in the LA. (B) Two-chamber transoesophageal echocardiographic view. The colour-Doppler image demonstrates a signiﬁ-
cant reduction of the mitral regurgitation after the successful implantation and release of two clips (arrow). (C) The ﬂuoroscopy right anterior
oblique projection shows the two clips attached to the mitral valve leaﬂets. The second clip is going to be released from the delivery catheter
system.
Figure 2 Post-procedural imaging of the mitral valve after clip
deployment. The newly created double-oriﬁce is indicated by
arrows in the three-dimensional (A) and two-dimensional echo-
cardiographic views (B). Echoes generated by the clip grasping
the leaﬂets (*) are evident below the mitral annulus plane in
the two-dimensional view.
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sided, and a value of P , 0.05 was considered to be signiﬁcant. All
data were processed using the Statistical Package for Social Sciences,
version 15 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Thirty-one patients [age 71 (IQR 62–79) years, male 81%] were
treated between August 2008 and July 2009. Demographic and
clinical characteristics are shown in Table 2. Eighteen patients
(58%) presented with functional disease and 13 patients (42%)
with organic degenerative disease (Table 3). Among patients with
functional MR, 67% had a previous history of coronary artery
disease. Logistic EuroSCORE and Society of Thoracic Surgeons
(STS) score were 14.3+11.9 and 10.3+8.8%, respectively.
Mean pulmonary and wedge pressures assessed by right catheter-
ization were 25.2+10.8 and 18.4+9.1 mmHg, respectively.
Procedure results
Twenty-one procedures were performed at one site (FH) and 10
at the other site (SRH). General anaesthesia was employed in all
patients except one, who was treated under a deep conscious
sedation because of contraindications to anaesthetic drugs. Mean
general anaesthesia time was 166+54 min. A clip was successfully
implanted in 19 patients (61%) and two clips in 12 patients (39%).
In no case, was clip implantation unsuccessful. The clip was
implanted in the central portion of the valve in 97% of patients.
In one case, was the clip implanted in the lateral commissure.
The aetiology of MR was degenerative in 10% of patients who
required one clip and 58% of patients who required two clips.
The device implantation time, deﬁned as the time from guide
insertion until CDS removal, did not signiﬁcantly diminish with
experience (Figure 5). Overall, the median device implantation
time was 80 (IQR 61–137) min, ranging from 35 to 188 min.
The ﬁrst 10 procedures had a median device implantation time
of 90 (IQR 65–158) min, the next 10 procedures had a median
device implantation time of 76 (IQR 55–140) min, and the ﬁnal
11 procedures had a mean device implantation time of 74 (IQR
50–113) min (P for trend ¼ 0.468). The median device implan-
tation time varied signiﬁcantly between one-clip and two-clip
cases [65 (IQR 50–74) vs. 151 (IQR 115–169) min, respectively,
P , 0.001] and non-signiﬁcantly between functional and degenera-
tive aetiologies [73 (IQR 58–117) vs. 113 (IQR 59–161) min,
respectively, P ¼ 0.357]. There was no procedural mortality.
Primary safety and efﬁcacy endpoint
MAEs occurred in two patients at 30 days, resulting in a primary
safety endpoint of 93.6% [95% conﬁdence interval (CI) 77.2–
98.9]. One patient, a 76-year-old man with thrombocytopenia
and renal failure on haemodialysis, died 2 weeks after the pro-
cedure from gastrointestinal bleeding. Another patient experi-
enced intra-procedural cardiac tamponade, after transseptal
puncture, requiring surgical subxiphoid drainage and blood transfu-
sion. Despite this complication, the clip was implanted successfully.
No patient underwent emergency cardiac surgery for a failed clip
implantation. No cases of clip detachment or embolization were
observed. There were no other complications, including access
site bleedings and transient ischaemic attacks.
Acute device success was observed in 30 of 31 patients (96.8%,
95% CI 81.5–99.8) (Figure 6). At 30 days, of the 28 patients with
MR ¼ 4þ before the procedure, 18 (58%) had an MR graded as
trivial to mild (0 to 1þ), 9 (29%) had an MR graded as mild to mod-
erate (1 to 2þ), and 1 patient had an MR graded as moderate to
severe (2 to 3þ). This latter patient was treated with two clips for
a degenerative MR. All three patients with MR ¼ 3þ before the pro-
cedure had an MR graded as trivial to mild (0 to 1þ)a t3 0d a y s .
Figure 4 Pulmonary wedge pressure recorded in basal con-
dition shows a high V wave (A) secondary to severe mitral regur-
gitation. After clip implantation, the V wave is reduced (B). The
parallel A-wave reduction indicates diminished end-diastolic
pressure. These variations in aggregate result in diminished
mean wedge pressure after clip implantation. In this case
example, the systemic pressure varied from 100/60 mmHg
before clip implantation to 130/70 mmHg after clip implantation,
following ﬂuid challenge and norepinephrine administration.
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class was I/II in 13% of patients and III/IV in 87% of patients.
Thirty days after the procedure, all patients (100%) were in
NYHA functional class I/II. Clinical symptoms were improved in
all patients. In none of the patients the dosage of diuretics was
increased after the procedure. Compared with baseline, diastolic
left ventricular diameter, left ventricular volume, and annular
septal–lateral dimension signiﬁcantly diminished at 30 days
(Table 4). The mitral valve area by planimetry was
4.4+1.1 cm
2 at baseline and 2.8+0.5 cm
2 at 30 days (P ,
0.001). Systolic left atrial dimension and LVEF did not vary
signiﬁcantly.
Discussion
The results of the initial Italian experience with the MitraClip
device in a cohort of 31 patients indicate that the percutaneous
edge-to-edge mitral valve repair is feasible and may be accom-
plished with favourable acute results. For the ﬁrst time, these ﬁnd-
ings apply to a different population from that enrolled in the pivotal
Endovascular Valve Edge-to-Edge Repair Study (EVEREST) trial.
8,12
Surgery is the current gold standard of treatment for patients
with symptomatic severe MR or asymptomatic severe MR with evi-
dence of left ventricular dysfunction or dilatation, as it represents
the only approach with deﬁned clinical success, providing sustained
...............................................................................................................................................................................
Table 1 Major inclusion and exclusion criteria
Inclusion criteria
Age 18 years or older
Moderate to severe (3þ) or severe (4þ) chronic mitral valve regurgitation with symptoms or without symptoms but LVEF , 60% or left ventricle end
systolic diameter . 45 mm
High-risk candidates for mitral valve surgery including cardiopulmonary bypass
Primary regurgitant jet originating from malcoaptation of the A2 and P2 scallops of the mitral valve; if a secondary jet exists, it must be considered
clinically insigniﬁcant
Presence of sufﬁcient leaﬂet tissue for a mechanical coaptation
Non-rheumatic/endocarditic valve morphology
Transseptal catheterization determined to be feasible by the treating physician
Exclusion criteria
Evidence of an acute myocardial infarction in the 12 weeks prior to the intended treatment
Need for any other cardiac surgery including surgery for coronary artery disease, atrial ﬁbrillation, pulmonic, aortic, or tricuspid valve disease
Mitral valve oriﬁce area ,4.0 cm
2
If leaﬂet ﬂail is present
a:
ﬂail width  15 mm
b
ﬂail gap  10 mm
c
If leaﬂet tethering is present:
coaptation depth  11 mm
d
coaptation length ,2m m
e
Severe mitral annular calciﬁcation
Any leaﬂet anatomy which may preclude clip implantation, proper clip positioning on the leaﬂets, or sufﬁcient reduction in MR
Haemodynamic instability deﬁned as systolic pressure ,90 mmHg without afterload reduction or cardiogenic shock or the need for inotropic support
or intra-aortic balloon pump
Need for emergency surgery for any reason
Systolic anterior motion of the mitral valve leaﬂet
Hypertrophic cardiomyopathy
Echocardiographic evidence of intra-cardiac mass, thrombus, or vegetation
History of, or active, endocarditis
History of, or active, rheumatic heart disease
History of atrial septal defect, whether repaired or not
History of patent foramen ovale associated with clinical symptoms (e.g. cerebral ischaemia) or previously repaired or when, in the judgement of the
investigator, an atrial septal aneurysm is present that may interfere with transseptal crossing
History of a stroke or documented TIA within the prior 6 months
Patients in whom TOE is contraindicated
LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack; TOE, transoesophageal echocardiography.
aFlail is deﬁned as when a leaﬂet has both ruptured chordae and a free edge that extends above the opposing leaﬂet or above the plane of the annulus during systole.
bFlail width is deﬁned as the width of ﬂail leaﬂet segment as measured along the line of coaptation in the short-axis view.
cFlail gap is deﬁned as the greatest distance between the ventricular side of the ﬂail leaﬂet segment to the atrial side of the opposing leaﬂet edge.
dCoaptation depth is deﬁned as the shortest distance between the coaptation of the leaﬂets and the annular plane.
eCoaptation length is deﬁned as the vertical length of leaﬂets that is in contact, or is available for contact, during mid-systole in the atrial-to-ventricular direction in the
four-chamber view.
C. Tamburino et al. 1386relief of symptoms or heart failure.
2,3 On the downside, despite its
proven effectiveness, cardiac surgery is associated with signiﬁcant
trauma, risk of complications, and extended post-operative recov-
ery period. Importantly, many patients with co-morbidities do not
undergo surgery because of the high perceived risk of periopera-
tive morbidity and mortality.
13
A broad consensus exists that surgical mitral valve repair should
be the ﬁrst choice of treatment for MR, when feasible, because of
improved clinical outcomes and avoidance of chronic
anti-coagulation compared with valve replacement surgery.
Among surgical repair techniques, the edge-to-edge or ‘double-
oriﬁce repair’ has gained wider use over time because of durable
results shown in selected surgically treated patients.
7,14 The
suture guarantees that the two leaﬂets move together properly
during systole and results in a 40–50% smaller effective diastolic
oriﬁce area than prior the procedure.
15
The MitraClip system has been designed and developed to
enable physicians to perform edge-to-edge valve repair while the
heart is beating as an alternative to the open chest, arrested
heart approach. Beneﬁts of using this device include avoidance of
chest incisions, cardiopulmonary bypass, and cardiac arrest, as
well as the ability to identify the optimum point for creating an
edge-to-edge repair and to assess the result of the mitral valve
repair while the heart is fully functional prior to completion of
the procedure. In addition, the procedure allows fully reversing
all steps prior to complete deployment of clip device. This
enables to test multiple sites along the line of coaptation if the
physician is not satisﬁed with initial MitraClip device placement
after the mitral valve leaﬂets have been grasped and approximated.
Of note, differently from surgery, the percutaneous edge-to-edge
procedure does not allow the concomitant execution of mitral
annuloplasty. Most surgeons perform annuloplasty at the time of
the initial surgical repair procedure to reduce the likelihood of
re-operation in the future. However, it has been suggested that
edge-to-edge repair, when used alone, preserves the anatomic
sphincter mechanism of the mitral valve and the systolic perform-




Table 2 Baseline demographic and clinical
characteristics
n 5 31
Age, median (IQR) 71 (62–79)
Age . 65 years 22 (71)
Male sex 25 (81)




Chronic obstructive pulmonary disease 0
History of congestive heart failure
b 11 (36)
History of coronary artery disease 14 (45)
Previous coronary artery bypass graft 2 (6)
Atrial ﬁbrillation 8 (26)
High-risk criteria for mitral valve surgery with cardiopulmonary
bypass
c
Contraindications to extracorporeal circulation 12 (39)
Logistic EuroSCORE . 20% 7 (23)
Autoimmune disease 5 (16)
Severe renal failure requiring haemodialysis 4 (13)
Hepatic cirrhosis 3 (10)
Data are expressed as counts and percentages if not otherwise speciﬁed. IQR,
interquartile range.
aDeﬁned as estimated glomerular ﬁltration rate less than 60 mL/min/1.73 m
2.
bDeﬁned as prior hospitalization with documentation of exertional dyspnoea,
fatigue, bilateral pedal oedema, orthopnoea, paroxysmal nocturnal dyspnoea,
acute pulmonary oedema, or rales.
cHigh-risk criteria in patients with EuroSCORE , 20% included contraindications
to cardiopulmonary bypass (e.g. pre-existing cancer, pulmonary, or cerebral
disease) and co-morbidities not included in the EuroSCORE but deemed at high
risk, based on the consensus between a local independent cardiologist and a
cardiac surgeon that conventional surgery would be associated with excessive
morbidity and mortality.
Figure 5 The learning curve of the study series displayed a
non-signiﬁcant reduction of the device time throughout the
study, which was also consistently seen in one- and two-clip
cases.
Figure 6 Baseline and 30-day mitral regurgitation grading.
................................................................................
Table 3 Mitral regurgitation aetiology
Functional/ischaemic 18 (58%)
Degenerative 13 (42%)
P2 prolapse/ﬂail 8 (26%)
Bileaﬂets prolapse/ﬂail 3 (10%)
A2 prolapse/ﬂail 2 (6%)
Edge-to-edge percutaneous mitral repair 1387Thirty-day safety and efﬁcacy outcomes of a series of 107
patients enrolled in the EVEREST and in the pre-randomization
phase of the EVEREST II (clinicaltrials.gov id NCT00209274)
pivotal trials have been recently reported.
12 In that cohort, 62%
of patients were older than 65 years, mean ejection fraction was
62%, and functional aetiology accounted for 21% of patients.
Acute procedural success was obtained in 74% of patients, and
64% were discharged with MR   1þ.
Different from the inclusion criteria of the pivotal trial, patients
deemed at high risk of periprocedural complications with surgery
were included in the present study. As a result, our patients
reﬂected a higher risk proﬁle than those enrolled in the
EVEREST trial: 71% of patients were older than 65 years, mean
ejection fraction was 42%, and a functional aetiology, with all the
inherent cardiac and extra-cardiac characteristics, was more fre-
quently the cause of MR, being observed in 58% of patients.
Despite this higher risk at baseline, we observed encouraging
results in our study population. Reductions on MR were achieved
in all patients, with 68% of patients who met the procedural goal
of reducing MR to mild (1þ) or less and 97% of patients with
MR  2þ.
Although the ﬁrst 10 procedures had a device implantation time
of 104 min and the ﬁnal 11 procedures were on average 15 min
shorter, we did not appreciate a statistically signiﬁcant learning
curve throughout the study period. However, the overall device
implantation time was more than 1 h shorter than that reported
in the EVEREST trial, despite a higher rate of procedures requiring
the placement of two clips. This difference may be partly explained
by lessons learnt by the initial experience with the device and a
higher rate of functional MR. Not surprisingly, in fact, device
implantation time was longer in procedures on degenerative
valve disease which more often required two-clip deployment.
Importantly, despite the relatively large MitraClip system being
manipulated inside the left chambers across the mitral oriﬁce for
more than 1 h in the majority of the cases, all the procedures
were characterized by haemodynamic stability of the patients,
including those with severe left ventricular dysfunction. The
ability of the device to grasp and remove the clip before deploy-
ment was critical to address some initial unsatisfactory degrees
of improvement in MR and then reposition the clip to achieve
the optimal result.
The safety of the device was also remarkable, with no cases of
clip detachment or embolization. One case of intra-procedural
cardiac tamponade was successfully managed. Haemostasis of the
24-F femoral venous access was obtained without any bleeding
issue. The early mortality rate of the study population was lower
than that predicted by its average baseline EuroSCORE, an index
which has also been shown to overestimate the risk of cardiac
surgery in high-risk patients.
17 Death occurred in one patient,
who suffered from multiple co-morbidities, including end-stage
chronic kidney disease and thrombocytopaenia. Percutaneous
mitral valve repair was offered as the only palliative alternative of
treatment to this patient, who presented with worsening symp-
toms of dyspnoea and died due to gastrointestinal bleeding 2
weeks after a successful procedure followed by symptoms relief.
Study limitations
Although positive, this study reports results obtained in a non-
randomized fashion on a very small sample of patients with func-
tional or degenerative MR selected on the basis of numerous
exclusion criteria. In addition, due to the novelty of the technique,
only a short follow-up was documented. Therefore, these study
results must be intended as preliminary. Larger series and longer
follow-up are warranted to determine the safety, efﬁcacy, and
durability of the MitraClip system enabling further investigation
on different patient populations, including patients with functional
and degenerative MR aetiology.
Another caveat is that the echocardiograms were not reviewed
by an independent Core-Lab, because the study was performed in
a clinical setting reproducing real world practice. In this study,
however, the grading of MR was accomplished by means of a vali-
dated integrative method and based on the consensus among at
least two expert observers.
Conclusions
The preliminary Italian experience with the MitraClip device indi-
cates that percutaneous edge-to-edge mitral valve repair is a feas-
ible approach that may be accomplished with favourable early
outcomes. Until more experience can be gained and indications
can be deﬁned, this new technology could apply for a high-risk
population in whom no viable option for mitral repair is available.
Whether mitral valve repair by percutaneous clip implantation may
represent a preferable alternative to surgery or medical therapy
alone is currently undeﬁned and needs to be proven by speciﬁcally
designed randomized trials.
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Systolic left atrial dimension
(mm)










LVEF (%) 42+17 43+14 0.541
Diastolic annular septal–
lateral dimension (mm)
37+53 2 +3 0.013
Mitral valve area (cm
2)




Data are expressed as mean+standard deviation.
aAssessed by planimetry.
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